Marc Van Dijk | CSO discovery and engineering
Fairjourney bio

Marc van Dijk, Ph.D. brings more than 25 years of experience in leading platform development and antibody discovery. Most recently, he served as Chief Scientific Officer at MiNK Therapeutics, where he contributed to advancing innovative therapies. Prior to that, he was previously Chief Technology Officer at Agenus, where he oversaw the development of Retrocyte Display™, the company’s proprietary antibody discovery platform. During this time, Dr. van Dijk led antibody discovery programs in collaboration with the Ludwig Institute for Cancer Research, contributing to the clinical development of key antibodies, including those targeting CTLA4, PD1, GITR, and OX40. Earlier in his career, he served as Chief Technology Officer at 4-Antibody, a subsidiary of Agenus, and as Vice President of Antibody Technology at Genmab, where he managed partnerships with Immunex (now Amgen) and Roche, and led numerous discovery projects, including Humax-CD20 (Arzerra™). He also held leadership roles at Innogenetics (now Fujirebio) as Director of Applied Research. Dr. van Dijk has held a tenure-track position in the Department of Immunology at the University Medical Center Utrecht and completed a postdoctoral fellowship in Molecular Biology at the University of California, San Diego. He earned his Ph.D. in Molecular Biology from Utrecht University.